About Caprice therapeutics

 At Caprice Therapeutics, we have a differentiated, diverse, proprietary portfolio of monoclonal anti-CD47 and anti-SIRPα antibodies that are engineered to provide robust blocking of the CD47/SIRPα pathway with reduced on-target side effects. Our platform focuses on proven antibodies that can modulate the immune system, block aberrant signaling pathways, and deliver targeted therapies directly to affected tissues. By honing in on the root causes of disease, our antibodies offer a more precise, effective, and safe treatment approach to current therapies.